Lv4
763 积分 2021-08-19 加入
An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease
1天前
已完结
Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials
1天前
已完结
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
1天前
已完结
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial
1天前
已关闭
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial
1天前
已完结
Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial
1天前
已完结
Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations
1天前
已完结
Oral strategies to target proprotein convertase subtilisin/kexin type 9 and lipoprotein(a): the new frontier of lipid lowering
1天前
求助中
Semaglutide for the treatment of obesity
10个月前
已完结
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial
10个月前
已完结
皖公网安备34019202002308
